Press Release

Experienced Biotech Executive Brings More Than 20 Years of Financial Leadership

Cambridge, Mass. (March 22, 2023) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Robert Gagnon as Chief Financial Officer.

“We are delighted to have Rob joining Remix as he brings a wealth of experience to the CFO role. His combination of financial acumen and tenure in the life science industry makes him an ideal fit,” said Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics.  “Rob is a great addition to our strong management team of industry veterans with deep domain expertise. His experience in all areas of biopharmaceutical finance, including his ability to grow organizations successfully and track record with public companies, will be invaluable as we advance our REMaster technology platform to bring innovative therapies to fight diseases with unmet need.” 

“I am truly excited to be joining Remix as we have a unique opportunity to change the course of various diseases with a novel platform approach that modulates RNA processing to address those diseases at their origins,” said Mr. Gagnon. “I look forward to working with my colleagues to build Remix into a leading biopharmaceutical company transforming the way we treat diseases.”

Mr. Gagnon brings more than 20 years of financial and commercial experience leading global finance operations. Prior to his appointment, he served as Chief Financial Officer and Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund. Mr. Gagnon has also held executive and financial leadership roles at numerous public and private biotechnology companies, including Verastem Oncology, Harvard Bioscience, Inc., Clean Harbors, Inc., and Biogen Idec, Inc. He has also worked in a variety of senior positions at Deloitte & Touche, LLP, and Price Waterhouse Coopers, LLP. He holds an M.B.A. from the MIT Sloan School of Management and a B.A. in Accounting from Bentley College.

Mr. Gagnon currently serves on the Board of Directors at Verastem Oncology and Purple Biotech.

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:
Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:
Will O’Connor  
Stern Investor Relations 
will.oconnor@sternir.com  
212-362-1200 

Industry Leader Brings Three Decades of Strategic Clinical and Corporate Expertise

Cambridge, Mass. (January 5, 2023) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Christopher Bowden, M.D., as Chief Medical Officer.

“We are especially pleased to welcome Chris to the Remix team as his wealth of strategic medical and corporate experience are ideally suited for this role. We look forward to leveraging his extensive clinical expertise as we advance programs from our REMaster platform toward the clinic,” said Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics.

“This is an exciting time to join the Remix team as they have demonstrated pre-clinical proof-of-concept for their novel platform approach to tackle disease drivers by modulating RNA processing,” said Dr. Bowden. “I look forward to working with my colleagues to translate this work and deliver new medicines for patients; starting with drugging the MYB oncogenic transcription factor that is broadly dysregulated in both solid tumors and hematological malignancies.”

Dr. Bowden joins Remix from Agios, where he served as a Strategic Advisor and Chief Medical Officer (CMO) from 2014-2022.  As CMO, Chris was responsible clinical development of the oncology and rare genetic disease portfolios that led to US approvals for the IDH inhibitors IDHIFA and TIBSOVO in AML, for TIBSOVO in cholangiocarcinoma and for PYRUKYND, a Pyruvate Kinase activator, for adults with Pyruvate Kinase Deficiency. Prior to joining Agios, Dr. Bowden was vice president product development oncology, franchise lead (Signaling Group) at Genentech, Inc., a member of the Roche Group. During Dr. Bowden’s eight-year tenure at Genentech, he was responsible for the successful development of several novel targeted oncology medicines, including Zelboraf™ for patients with BRAF V600E positive melanoma and Tarceva™ for patients with EGFR activating mutation positive, non-small cell lung cancer. Before that, Dr. Bowden was the executive director for EMEA (Europe, Middle East, Africa) regions for Bristol-Myers Squibb. In this role, he led medical affairs strategies for cancer, immunology and pain medicines. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development at Pharmacia Corporation and Janssen Pharmaceutical, Inc. Prior to his industry experience, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center, where he participated in numerous industry and cooperative group trials.

Dr. Bowden received his M.D. from Hahnemann University School of Medicine in Philadelphia after which he completed his internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He conducted his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology.

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:
Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:
Will O’Connor  
Stern Investor Relations 
will.oconnor@sternir.com  
212-362-1200  

Cambridge, Mass. (December 8, 2022) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that executive management will present at the 5th Annual RNA-Targeted Drug Discovery Summit to be held December 14-15, 2022 in Boston.

Podium Presentation:

Title: Novel Approaches to Reprogram RNA Processing with Small Molecules
Date/Time: Wednesday, December 14 at 9:30 a.m. ET
Presenter: Peter Smith, Ph.D., Chief Executive Officer

Panel Discussion:

Title: Exploring the Future of RNA Investment & Collaborations Space for Small Molecules
Date/Time: Wednesday, December 14 at 11:30 a.m. ET
Presenter: Heather Wasserman, Ph.D., Chief Operating Officer and Chief Business Officer

“We look forward to disclosing our lead program and presenting our novel approach to reprogramming RNA processing among an audience of researchers, clinicians and other industry leaders. Our innovative REMaster technology platform holds the promise to bring effective new medicines to patients in need, and forums such as these help to advance those efforts,” said Dr. Smith.

About Remix Therapeutics
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:
Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:
Will O’Connor
Stern Investor Relations
will.oconnor@sternir.com
212-362-1200

Cambridge, Mass. (June 1, 2022) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4:30 p.m. ET in New York.

A live webcast of the presentation may be accessed here and on the News & Media section of the Remix website. A replay of the webcast will be available for approximately 90 days following the presentation.

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. The REMaster technology platform makes it possible to identify patterns in RNA processing and exploit them to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:

Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:

Will O’Connor  
Stern Investor Relations 
will.oconnor@sternir.com  
212-362-1200  

Supports Novel Small Molecule Therapeutic Approach Designed to Reprogram RNA Processing and Modulate Gene Expression

Cambridge, Mass. (May 17, 2022) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced the close of a $70 million Series B financing. Surveyor (a Citadel company) joined the Series B syndicate alongside existing investors Foresite Capital, Atlas Venture, The Column Group, Arch Venture Partners, Alexandria Venture Investments, and Casdin Capital. The funds will support development of the company’s REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics.

“We are pleased to announce this Series B financing that reflects the significant progress we have made to advance our novel platform and programs modulating RNA processing. With the support of our new and existing investors, we will continue on our path to address disease drivers at their origin,” said Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics. “This financing will support further development of our REMaster platform, which enables the design of molecules that can selectively degrade RNA, enhance RNA expression, induce exon skipping, or rescue genetic lesions. This technology will transform how diseases are treated.”

Fueled by its proprietary technology platform, Remix is leveraging the power of data analytics, bespoke high-throughput screening technologies, and next generation chemistry to advance a pipeline of breakthrough therapies. The company’s innovative approach has the unique ability to precisely identify and target RNA processing steps to enhance or eliminate protein function, or to correct dysregulation in disease.

“Drug discovery has primarily centered on targeting proteins but many genetically validated disease mechanisms and targets remain unaddressed. Alternate approaches to building new medicines are needed, so we are thrilled to support Remix’s mission to create a new set of tools to not only treat disease in new ways, but to treat diseases more effectively,” said Michael Rome, PhD, Managing Director at Foresite Capital.

Remix recently entered into a strategic collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix’s REMaster drug discovery platform.

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. The REMaster technology platform makes it possible to identify patterns in RNA processing and exploit them to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:

Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:

Will O’Connor  
Stern Investor Relations  will.oconnor@sternir.com  
212-362-1200